Clinical trials
Recurrent Glioblastoma, IDH-Wildtype clinical trials
Below are recruiting recurrent glioblastoma, idh-wildtype clinical trials, each written for real people, not researchers. We’re tracking 26 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07091864Recruiting
Glucose monitoring for brain tumor patients
This study tests whether using a continuous glucose monitor (a small device that tracks blood sugar levels) can help manage high blood sugar in people newly diagnosed with glioblastoma, a type of brain cancer. It aims to see if this monitoring can improve overall health during treatment.
Phoenix, ArizonaAges 18 years+ - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07520214Enrolling by invitationEarly Phase 1
Cancer vaccine to prevent glioblastoma recurrence
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
Phoenix, ArizonaAges 18 years+ - NCT05465954RecruitingPhase 2
Testing efinetakin and pembrolizumab for recurrent glioblastoma
This Phase 2 trial studies efinetakin alfa plus pembrolizumab for adults with recurrent glioblastoma (a fast-growing brain tumor). It aims to shrink or control the tumor and help patients live longer and better after standard treatments like surgery, radiation, and temozolomide.
Rochester, MinnesotaAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05789394RecruitingPhase 1
Stem cell treatment for recurrent brain tumor surgery
This Phase 1 study tests an “allogenic” stem cell product made from donated fat tissue to treat recurrent glioblastoma or certain recurrent astrocytoma. It gives the treatment around the time of a repeat brain surgery, and focuses on safety while also studying why it might help.
Jacksonville, FloridaAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT05941234Recruiting
Studying stem cells and blood patterns in glioblastoma
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
RomeAges 18 years+ - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06410248RecruitingPhase 1
Triapine and temozolomide for recurrent glioblastoma
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
Chicago, IllinoisAges 18 years+ - NCT06552260RecruitingEarly Phase 1
Troriluzole before surgery for recurrent glioblastoma
This trial tests whether an investigational drug called troriluzole can help people with recurrent glioblastoma (a type of brain tumor). You would take the drug for a short time before your planned surgery, so researchers can study how the drug affects your tumor tissue. The goal is to see if it might slow tumor growth.
Boston, MassachusettsAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT07297212RecruitingPhase 2
Testing the drug pumitamig for recurrent glioblastoma
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
BeijingAges 18–75 - NCT07301268RecruitingPhase 2
GI-102 with or without pembrolizumab before brain surgery
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
Rochester, MinnesotaAges 18 years+ - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+ - NCT07100730RecruitingPhase 3
A new drug for recurrent glioblastoma vs standard care
This trial tests a new targeted drug, TLX101-Tx, added to standard care for people with glioblastoma that has come back after initial treatment. It aims to see if the combination helps control the tumor better than standard care alone.
Gold Coast, QueenslandAges 18 years+ - NCT07579208RecruitingPhase 1
CAR NK cells for recurrent glioblastoma brain tumors
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
Houston, TexasAges 18 years+ - NCT06672575RecruitingPhase 1/Phase 2
Ivonescimab for recurrent glioblastoma
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
Houston, TexasAges 18 years+ - NCT07616986Recruiting
Laser heat treatment for early-returning brain cancer
This trial tests a minimally invasive laser procedure (LITT) to treat glioblastoma that comes back very soon after initial treatment. The goal is to see if laser heat can destroy the tumor before standard radiation and chemotherapy begin, potentially improving outcomes.
BernAges 18 years+
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Recurrent Glioblastoma, IDH-Wildtype trials by city
Studies with a site in or near these metro areas.
Recurrent Glioblastoma, IDH-Wildtype trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for recurrent glioblastoma, idh-wildtype?
- Yes. Clin2 currently lists 26 recruiting recurrent glioblastoma, idh-wildtype studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent glioblastoma, idh-wildtype trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent glioblastoma, idh-wildtype trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.